

Human PILRA Protein

Cat. No. PRA-HM201



Description

Source	Recombinant Human PILRA Protein is expressed from HEK293 with hFc tag at the C-Terminus.
	It contains Gln20-Ala197.
Accession	Q9UKJ1
Molecular Weight	The protein has a predicted MW of 47 kDa. Due to glycosylation, the protein migrates to 60-68 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE
	> 95% as determined by HPLC

Formulation and Storage

Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Alzheimer's disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognitive performance; Mild Cognitive Impairment (MCI) is instead an objective decline in cognitive performance that does not reach pathology. Paired immunoglobulin-like type 2 receptor alpha (PILRA) is a cell surface inhibitory receptor that was recently suggested to be involved in AD pathogenesis. In particular, the arginine-to-glycine substitution in position 78 (R78, rs1859788) was shown to be protective against AD.

Assay Data


Tris-Bis PAGE



Human PILRA on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human PILRA is greater than 95% as determined by SEC-HPLC.